Journal List > J Korean Endocr Soc > v.23(2) > 1003423

Kim, Kim, Kim, Rhee, Choi, Kim, and Shong: CAG Repeats in the Androgen Receptor Polymorphism do not Correlate with Thyrotoxic Periodic Paralysis

Abstract

Background

Thyrotoxic periodic paralysis (TPP) occurs mostly in males, but no studies have addressed the role of androgen in the disease. Hyperinsulinemia can precipitate acute paralysis in TPP patients. CAG repeats in the androgen receptor (AR), an X-linked gene, correlate with serum insulin levels.

Aim

To evaluate whether CAG repeats in the AR gene might predict the susceptibility to TPP in Korean male Graves' patients.

Methods

We evaluated CAG repeat length in a series of 33 male TPP patients and 48 control patients by direct sequencing of the PCR product of the AR promoter site. Control patients were male Graves' patients without a history of paralysis.

Results

The CAG repeat length varied from 15 to 34 (median of 23). The upper quartile of CAG length was equal to or above 26 repeats (long AR). The distribution of long AR was 0.30 in TPP and 0.15 in control patients, respectively (odds ratio, 2.51; 95% confidence interval, 0.92~6.85; P = 0.09).

Conclusion

AR gene polymorphisms may not confer genetic susceptibility to TPP in Korean male patients with Graves' disease.

Figures and Tables

Fig. 1
Representative sequences of androgen receptor gene CAG repeat. The CAG repeat began at nucleotide number 87 and end at nucleotide number 149. This meant that 21 CAG repeat was present in the sample.
jkes-23-117-g001
Fig. 2
Distribution of CAG repeats of the promoter lesion of the androgen receptor gene in male Graves' patients with (TPP) or without (GD only) history of thyrotoxic periodic paralysis.
jkes-23-117-g002
Table 1
Polymorphism at the androgen receptor gene in male patients with thyrotoxic periodic paralysis (TPP) and male Graves' patients without previous history of paralysis (GD only)
jkes-23-117-i001

Genotype frequencies were given in parentheses.

*P values was calculated by Fisher's exact test.

The CAG length was equal or above 26 repeats.

The CAG length below 26 repeats.

References

1. Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 2006. 91:2490–2495.
2. Tang NL, Chow CC, Ko GT, Tai MH, Kwok R, Yao XQ, Cockram CS. The alpha1S subunit of the L-type calcium channel is not a predisposition gene for thyrotoxic periodic paralysis . Clin Endocrinol (Oxf). 2007. 66:229–234.
3. Dias da Silva MR, Cerutti JM, Tengan CH, Furuzawa GK, Vieira TC, Gabbai AA, Maciel RM. Mutations linked to familial hypokalaemic periodic paralysis in the calcium channel alpha1 subunit gene (Cav1.1) are not associated with thyrotoxic hypokalaemic periodic paralysis. Clin Endocrinol (Oxf). 2002. 56:367–375.
4. Kung AW, Lau KS, Fong GC, Chan V. Association of novel single nucleotide polymorphisms in the calcium channel alpha 1 subunit gene (Cav1.1) and thyrotoxic periodic paralysis. J Clin Endocrinol Metab. 2004. 89:1340–1345.
5. Ng WY, Lui KF, Thai AC, Cheah JS. Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. Thyroid. 2004. 14:187–190.
6. Wang W, Jiang L, Ye L, Zhu N, Su T, Guan L, Li X, Ning G. Mutation screening in Chinese hypokalemic periodic paralysis patients. Mol Genet Metab. 2006. 87:359 –363.
7. Dias da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab. 2002. 87:4881–4884.
8. Lane AH, Markarian K, Braziunene I. Thyrotoxic periodic paralysis associated with a mutation in the sodium channel gene SCN4A. J Pediatr Endocrinol Metab. 2004. 17:1679–1682.
9. Kung AW, Lau KS, Cheung WM, Chan V. Thyrotoxic periodic paralysis and polymorphisms of sodium -potassium ATPase genes. Clin Endocrinol (Oxf). 2006. 64:158–161.
10. Kim TY, Song JY, Kim WB, Shong YK. Arg16Gly polymorphism in beta2-adrenergic receptor gene is not associated with thyrotoxic periodic paralysis in Korean male patients with Graves' disease. Clin Endocrinol (Oxf). 2005. 62:585–589.
11. Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine Baltimore. 1992. 71:109–120.
12. Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ. 1991. 303:1096–1099.
13. Mulder JE. Thyroid disease in women. Med Clin North Am. 1998. 82:103–125.
14. Sweeney G, Klip A. Regulation of the Na+/K+-ATPase by insulin: why and how? Mol Cell Biochem. 1998. 182:121–133.
15. Lee KO, Taylor EA, Oh VM, Cheah JS, Aw SE. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. Lancet. 1991. 337:1063–1064.
16. Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia. 2003. 46:31–39.
17. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing;available from: http://www.R-project.org.
18. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992. 12:241–253.
19. Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non prostate cell lines. J Mol Endocrinol. 2000. 25:85–96.
20. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2000. 60:5111–5116.
21. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab. 1997. 82:3777–3782.
22. Mifsud A, Sim CK, Boettger-Tong H, Moreira S, Lamb DJ, Lipshultz LI, Yong EL. Trinucleotide (CAG) repeat polymorphisms in the androgen receptor gene: molecular markers of risk for male infertility. Fertil Steril. 2001. 75:275–281.
23. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003. 26:76–83.
24. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992. 12:241–253.
25. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000. 92:2009–2017.
26. van Houten ME, Gooren LJ. Differences in reproductive endocrinology between Asian men and Caucasian men--a literature review. Asian J Androl. 2000. 2:13–20.
27. Wang G, Chen G, Wang X, Zhong J, Lu J. The polymorphism of (CAG)n repeats within androgen receptor gene among Chinese male population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001. 18:456 –458.
TOOLS
Similar articles